"Study","Study.year","Analysis.name","Analysis.number","Subgroup.number","Experimental.cases","Experimental.N","Control.cases","Control.N","Experimental.mean","Experimental.SD","Control.mean","Control.SD","GIV.Mean","GIV.SE","Mean","CI.start","CI.end","Variance","Weight","analysis_key","dataset_name","exp_cases_gt_n","ctrl_cases_gt_n","exp_cases_lt0","ctrl_cases_lt0","exp_n_le0","ctrl_n_le0","exp_cases_nonint","ctrl_cases_nonint","exp_n_nonint","ctrl_n_nonint","double_zero","all_events","sparse_events","exp_sd_le0","ctrl_sd_le0","variance_negative","giv_se_negative","ci_inverted","ci_mismatch"
"Chan 2017",2017,"Analysis 1.1. Outcome 1: Proportion of participants with serious adverse events",1,NA,3,49,2,50,0,0,0,0,0,0,1.549803,0.258743,9.282903,0,100,"1::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Masoodi 2013",2013,"Analysis 1.1. Outcome 1: Proportion of participants with serious adverse events",1,NA,0,50,0,50,0,0,0,0,0,0,NA,NA,NA,0,NA,"1::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Mirhashemi 2022",2022,"Analysis 1.1. Outcome 1: Proportion of participants with serious adverse events",1,NA,0,30,0,30,0,0,0,0,0,0,NA,NA,NA,0,NA,"1::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Rajendra 2022",2022,"Analysis 1.1. Outcome 1: Proportion of participants with serious adverse events",1,NA,0,15,0,30,0,0,0,0,0,0,NA,NA,NA,0,NA,"1::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Chan 2017",2017,"Analysis 1.2. Outcome 1: Proportion of participants with serious adverse events: sensitivity analysis 'best-worst' case scenario",2,NA,3,49,2,50,0,0,0,0,0,0.890234242659044,1.549803,0.258743,9.282903,0.792517006802721,50.71069,"2::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Masoodi 2013",2013,"Analysis 1.2. Outcome 1: Proportion of participants with serious adverse events: sensitivity analysis 'best-worst' case scenario",2,NA,0,50,0,50,0,0,0,0,0,0,NA,NA,NA,0,NA,"2::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Mirhashemi 2022",2022,"Analysis 1.2. Outcome 1: Proportion of participants with serious adverse events: sensitivity analysis 'best-worst' case scenario",2,NA,0,30,5,30,0,0,0,0,0,1.49036846339488,0.117015,0.019042,0.719081,2.22119815668203,49.28931,"2::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Rajendra 2022",2022,"Analysis 1.2. Outcome 1: Proportion of participants with serious adverse events: sensitivity analysis 'best-worst' case scenario",2,NA,0,15,0,30,0,0,0,0,0,0,NA,NA,NA,0,NA,"2::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Chan 2017",2017,"Analysis 1.3. Outcome 1: Proportion of participants with serious adverse events: sensitivity analysis 'worst-best' case scenario",3,NA,3,49,2,50,0,0,0,0,0,0.890234242659044,1.549803,0.258743,9.282903,0.792517006802721,62.329019,"3::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Masoodi 2013",2013,"Analysis 1.3. Outcome 1: Proportion of participants with serious adverse events: sensitivity analysis 'worst-best' case scenario",3,NA,0,50,0,50,0,0,0,0,0,0,NA,NA,NA,0,NA,"3::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Mirhashemi 2022",2022,"Analysis 1.3. Outcome 1: Proportion of participants with serious adverse events: sensitivity analysis 'worst-best' case scenario",3,NA,3,30,0,30,0,0,0,0,0,1.48920849295318,7.926214,0.792662,79.25808,2.21774193548387,37.670981,"3::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Rajendra 2022",2022,"Analysis 1.3. Outcome 1: Proportion of participants with serious adverse events: sensitivity analysis 'worst-best' case scenario",3,NA,0,15,0,30,0,0,0,0,0,0,NA,NA,NA,0,NA,"3::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Atarodi 2022",2022,"Analysis 1.4. Outcome 2: ALT (U/L)",4,NA,0,30,0,30,47.16,30.82,47.14,21.23,0,6.87053400190002,0.02,-13.371901,13.411901,47.2042374712644,5.515433,"4::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Masoodi 2013",2013,"Analysis 1.4. Outcome 2: ALT (U/L)",4,NA,0,50,0,50,68.54,5.54,73.32,5.58,0,0,-4.78,-6.959494,-2.600506,0,32.204573,"4::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Memon 2015",2015,"Analysis 1.4. Outcome 2: ALT (U/L)",4,NA,0,33,0,31,39.3,10.9,51.2,19.1,0,0,-11.9,-19.583551,-4.216449,0,12.858145,"4::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mirhashemi 2022",2022,"Analysis 1.4. Outcome 2: ALT (U/L)",4,NA,0,30,0,30,34.59,17.44,47.68,10.88,0,3.85660852736356,-13.09,-20.445551,-5.734449,14.8734293333333,13.600551,"4::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Rajendra 2022",2022,"Analysis 1.4. Outcome 2: ALT (U/L)",4,NA,0,15,0,30,14.86,4.62,19.03,7.05,0,0,-4.17,-7.609561,-0.730439,0,26.92152,"4::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Solhi 2014",2014,"Analysis 1.4. Outcome 2: ALT (U/L)",4,NA,0,40,0,40,38.4,11.8,52.3,29.9,0,5.68507099850692,-13.9,-23.86141,-3.93859,32.3200322580645,8.899778,"4::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Atarodi 2022",2022,"Analysis 1.5. Outcome 2: ALT (U/L): sensitivity analysis fixed-effect model",5,NA,0,30,0,30,47.16,30.82,47.14,21.23,0,6.87053400190002,0.02,-13.371901,13.411901,47.2042374712644,1.610978,"5::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Masoodi 2013",2013,"Analysis 1.5. Outcome 2: ALT (U/L): sensitivity analysis fixed-effect model",5,NA,0,50,0,50,68.54,5.54,73.32,5.58,0,0,-4.78,-6.959494,-2.600506,0,60.822282,"5::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Memon 2015",2015,"Analysis 1.5. Outcome 2: ALT (U/L): sensitivity analysis fixed-effect model",5,NA,0,33,0,31,39.3,10.9,51.2,19.1,0,0,-11.9,-19.583551,-4.216449,0,4.893845,"5::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mirhashemi 2022",2022,"Analysis 1.5. Outcome 2: ALT (U/L): sensitivity analysis fixed-effect model",5,NA,0,30,0,30,34.59,17.44,47.68,10.88,0,3.85660852736356,-13.09,-20.445551,-5.734449,14.8734293333333,5.34003,"5::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Rajendra 2022",2022,"Analysis 1.5. Outcome 2: ALT (U/L): sensitivity analysis fixed-effect model",5,NA,0,15,0,30,14.86,4.62,19.03,7.05,0,0,-4.17,-7.609561,-0.730439,0,24.421261,"5::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Solhi 2014",2014,"Analysis 1.5. Outcome 2: ALT (U/L): sensitivity analysis fixed-effect model",5,NA,0,40,0,40,38.4,11.8,52.3,29.9,0,5.68507099850692,-13.9,-23.86141,-3.93859,32.3200322580645,2.911605,"5::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Atarodi 2022",2022,"Analysis 1.6. Outcome 3: AST (U/L)",6,NA,0,30,0,30,44.84,24.87,45.54,17.29,0,0,-0.7,-11.538802,10.138802,0,0,"6::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Masoodi 2013",2013,"Analysis 1.6. Outcome 3: AST (U/L)",6,NA,0,50,0,50,54.7,5.51,61.56,3.39,0,0,-6.86,-8.653173,-5.066827,0,0,"6::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Memon 2015",2015,"Analysis 1.6. Outcome 3: AST (U/L)",6,NA,0,33,0,31,39.3,7.5,35.9,11.7,0,0,3.4,-1.448823,8.248823,0,0,"6::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mirhashemi 2022",2022,"Analysis 1.6. Outcome 3: AST (U/L)",6,NA,0,30,0,30,30.22,15.94,40.04,13.39,0,0,-9.82,-17.269373,-2.370627,0,0,"6::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Rajendra 2022",2022,"Analysis 1.6. Outcome 3: AST (U/L)",6,NA,0,15,0,30,24.38,4.77,25.7,7.56,0,0,-1.32,-4.945658,2.305658,0,0,"6::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Solhi 2014",2014,"Analysis 1.6. Outcome 3: AST (U/L)",6,NA,0,40,0,40,30.5,8.2,36.2,12.4,0,0,-5.7,-10.306958,-1.093042,0,0,"6::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Rajendra 2022",2022,"Analysis 1.7. Outcome 4: GGT (U/L)",7,NA,0,15,0,30,24.52,5.73,32.82,8.21,0,0,-8.3,-12.427883,-4.172117,0,100,"7::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Chan 2017",2017,"Analysis 1.8. Outcome 5: Proportion of participants with non-serious adverse events",8,NA,13,49,9,50,0,0,0,0,0,0,1.473923,0.694105,3.129857,0,25.723837,"8::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mirhashemi 2022",2022,"Analysis 1.8. Outcome 5: Proportion of participants with non-serious adverse events",8,NA,0,30,0,30,0,0,0,0,0,0,NA,NA,NA,0,NA,"8::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Navarro 2019",2019,"Analysis 1.8. Outcome 5: Proportion of participants with non-serious adverse events",8,NA,15,27,6,13,0,0,0,0,0,0.345504297184882,1.203704,0.611541,2.369264,0.119373219373219,31.812058,"8::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Navarro 2019",2019,"Analysis 1.8. Outcome 5: Proportion of participants with non-serious adverse events",8,NA,17,26,6,12,0,0,0,0,0,0,1.307692,0.695671,2.458145,0,36.621785,"8::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Rajendra 2022",2022,"Analysis 1.8. Outcome 5: Proportion of participants with non-serious adverse events",8,NA,2,15,4,30,0,0,0,0,0,0,1,0.205939,4.855798,0,5.84232,"8::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Chan 2017",2017,"Analysis 1.9. Outcome 5: Proportion of participants with non-serious adverse events: sensitivity analysis on trials at 'low' risk of bias",9,NA,13,49,9,50,0,0,0,0,0,0,1.473923,0.694105,3.129857,0,27.319956,"9::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Navarro 2019",2019,"Analysis 1.9. Outcome 5: Proportion of participants with non-serious adverse events: sensitivity analysis on trials at 'low' risk of bias",9,NA,15,27,6,13,0,0,0,0,0,0.345504297184882,1.203704,0.611541,2.369264,0.119373219373219,33.785941,"9::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Navarro 2019",2019,"Analysis 1.9. Outcome 5: Proportion of participants with non-serious adverse events: sensitivity analysis on trials at 'low' risk of bias",9,NA,17,26,6,12,0,0,0,0,0,0,1.307692,0.695671,2.458145,0,38.894102,"9::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Chan 2017",2017,"Analysis 1.10. Outcome 5: Proportion of participants with non-serious adverse events: sensitivity analysis fixed-effect model",10,NA,13,49,9,50,0,0,0,0,0,0,1.473923,0.694105,3.129857,0,31.947932,"10::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mirhashemi 2022",2022,"Analysis 1.10. Outcome 5: Proportion of participants with non-serious adverse events: sensitivity analysis fixed-effect model",10,NA,0,30,0,30,0,0,0,0,0,0,NA,NA,NA,0,NA,"10::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Navarro 2019",2019,"Analysis 1.10. Outcome 5: Proportion of participants with non-serious adverse events: sensitivity analysis fixed-effect model",10,NA,15,27,6,13,0,0,0,0,0,0.345504297184882,1.203704,0.611541,2.369264,0.119373219373219,29.046538,"10::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Navarro 2019",2019,"Analysis 1.10. Outcome 5: Proportion of participants with non-serious adverse events: sensitivity analysis fixed-effect model",10,NA,17,26,6,12,0,0,0,0,0,0,1.307692,0.695671,2.458145,0,29.442884,"10::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Rajendra 2022",2022,"Analysis 1.10. Outcome 5: Proportion of participants with non-serious adverse events: sensitivity analysis fixed-effect model",10,NA,2,15,4,30,0,0,0,0,0,0.856348838577675,1,0.205939,4.855798,0.733333333333333,9.562646,"10::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Chan 2017",2017,"Analysis 1.11. Outcome 5: Proportion of participants with non-serious adverse events: sensitivity analysis 'best-worst' case scenario",11,NA,13,49,9,50,0,0,0,0,0,0,1.473923,0.694105,3.129857,0,25.270594,"11::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mirhashemi 2022",2022,"Analysis 1.11. Outcome 5: Proportion of participants with non-serious adverse events: sensitivity analysis 'best-worst' case scenario",11,NA,0,30,5,30,0,0,0,0,0,0,0.090909,0.005248,1.574659,0,1.761958,"11::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Navarro 2019",2019,"Analysis 1.11. Outcome 5: Proportion of participants with non-serious adverse events: sensitivity analysis 'best-worst' case scenario",11,NA,17,26,6,12,0,0,0,0,0,0,1.307692,0.695671,2.458145,0,35.976524,"11::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Navarro 2019",2019,"Analysis 1.11. Outcome 5: Proportion of participants with non-serious adverse events: sensitivity analysis 'best-worst' case scenario",11,NA,15,27,6,13,0,0,0,0,0,0.345504297184882,1.203704,0.611541,2.369264,0.119373219373219,31.251543,"11::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Rajendra 2022",2022,"Analysis 1.11. Outcome 5: Proportion of participants with non-serious adverse events: sensitivity analysis 'best-worst' case scenario",11,NA,2,15,4,30,0,0,0,0,0,0,1,0.205939,4.855798,0,5.739381,"11::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Chan 2017",2017,"Analysis 1.12. Outcome 5: Proportion of participants with non-serious adverse events: sensitivity analysis 'worst-best' case scenario",12,NA,13,49,9,50,0,0,0,0,0,0,1.473923,0.694105,3.129857,0,25.291438,"12::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mirhashemi 2022",2022,"Analysis 1.12. Outcome 5: Proportion of participants with non-serious adverse events: sensitivity analysis 'worst-best' case scenario",12,NA,3,30,0,30,0,0,0,0,0,0,7,0.377133,129.927767,0,1.680928,"12::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Navarro 2019",2019,"Analysis 1.12. Outcome 5: Proportion of participants with non-serious adverse events: sensitivity analysis 'worst-best' case scenario",12,NA,17,26,6,12,0,0,0,0,0,0,1.307692,0.695671,2.458145,0,36.006199,"12::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Navarro 2019",2019,"Analysis 1.12. Outcome 5: Proportion of participants with non-serious adverse events: sensitivity analysis 'worst-best' case scenario",12,NA,15,27,6,13,0,0,0,0,0,0.345504297184882,1.203704,0.611541,2.369264,0.119373219373219,31.277321,"12::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Rajendra 2022",2022,"Analysis 1.12. Outcome 5: Proportion of participants with non-serious adverse events: sensitivity analysis 'worst-best' case scenario",12,NA,2,15,4,30,0,0,0,0,0,0,1,0.205939,4.855798,0,5.744115,"12::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Chan 2017",2017,"Analysis 1.13. Outcome 6: Proportion of participants without improvement of steatosis",13,NA,40,49,37,50,0,0,0,0,0,0,1.103144,0.89306,1.362649,0,43.548907,"13::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Navarro 2019",2019,"Analysis 1.13. Outcome 6: Proportion of participants without improvement of steatosis",13,NA,20,26,11,12,0,0,0,0,0,0.167145889946429,0.839161,0.639975,1.100341,0.0279377485259838,30.026031,"13::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Navarro 2019",2019,"Analysis 1.13. Outcome 6: Proportion of participants without improvement of steatosis",13,NA,22,27,11,13,0,0,0,0,0,0.149678062532632,0.962963,0.718131,1.291266,0.0224035224035223,26.425061,"13::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Chan 2017",2017,"Analysis 1.14. Outcome 6: Proportion of participants without improvement of steatosis: sensitivity analysis fixed-effect model",14,NA,40,49,37,50,0,0,0,0,0,0,1.103144,0.89306,1.362649,0,55.053166,"14::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Navarro 2019",2019,"Analysis 1.14. Outcome 6: Proportion of participants without improvement of steatosis: sensitivity analysis fixed-effect model",14,NA,20,26,11,12,0,0,0,0,0,0.25575479547902,0.839161,0.639975,1.100341,0.0654105154105154,22.625705,"14::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Navarro 2019",2019,"Analysis 1.14. Outcome 6: Proportion of participants without improvement of steatosis: sensitivity analysis fixed-effect model",14,NA,22,27,11,13,0,0,0,0,0,0.149678062532632,0.962963,0.718131,1.291266,0.0224035224035223,22.321129,"14::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Chan 2017",2017,"Analysis 1.15. Outcome 7: Proportion of participants without improvement of lobular inflammation",15,NA,33,49,35,50,0,0,0,0,0,0,0.962099,0.737139,1.255713,0,44.175315,"15::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Navarro 2019",2019,"Analysis 1.15. Outcome 7: Proportion of participants without improvement of lobular inflammation",15,NA,21,26,10,12,0,0,0,0,0,0,0.969231,0.707359,1.32805,0,31.588788,"15::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Navarro 2019",2019,"Analysis 1.15. Outcome 7: Proportion of participants without improvement of lobular inflammation",15,NA,21,27,10,13,0,0,0,0,0,0.183463712103875,1.011111,0.705723,1.44865,0.0336589336589336,24.235896,"15::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Chan 2017",2017,"Analysis 1.16. Outcome 7: Proportion of participants without improvement of lobular inflammation: sensitivity analysis fixed-effect model",16,NA,33,49,35,50,0,0,0,0,0,0,0.962099,0.737139,1.255713,0,56.034427,"16::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Navarro 2019",2019,"Analysis 1.16. Outcome 7: Proportion of participants without improvement of lobular inflammation: sensitivity analysis fixed-effect model",16,NA,21,26,10,12,0,0,0,0,0,0,0.969231,0.707359,1.32805,0,22.13175,"16::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Navarro 2019",2019,"Analysis 1.16. Outcome 7: Proportion of participants without improvement of lobular inflammation: sensitivity analysis fixed-effect model",16,NA,21,27,10,13,0,0,0,0,0,0.183463712103875,1.011111,0.705723,1.44865,0.0336589336589336,21.833823,"16::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Chan 2017",2017,"Analysis 1.17. Outcome 8: Proportion of participants without improvement of hepatocyte ballooning",17,NA,29,49,33,50,0,0,0,0,0,0,0.896722,0.660324,1.217752,0,32.067103,"17::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Navarro 2019",2019,"Analysis 1.17. Outcome 8: Proportion of participants without improvement of hepatocyte ballooning",17,NA,22,26,10,12,0,0,0,0,0,0.108334720825836,1.015385,0.751106,1.37265,0.0117364117364117,33.040178,"17::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Navarro 2019",2019,"Analysis 1.17. Outcome 8: Proportion of participants without improvement of hepatocyte ballooning",17,NA,22,27,11,13,0,0,0,0,0,0.149678062532632,0.962963,0.718131,1.291266,0.0224035224035223,34.89272,"17::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Chan 2017",2017,"Analysis 1.18. Outcome 8: Proportion of participants without improvement of hepatocyte ballooning: sensitivity analysis fixed-effect model",18,NA,29,49,33,50,0,0,0,0,0,0,0.896722,0.660324,1.217752,0,53.376141,"18::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Navarro 2019",2019,"Analysis 1.18. Outcome 8: Proportion of participants without improvement of hepatocyte ballooning: sensitivity analysis fixed-effect model",18,NA,22,26,10,12,0,0,0,0,0,0.108334720825836,1.015385,0.751106,1.37265,0.0117364117364117,22.359501,"18::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Navarro 2019",2019,"Analysis 1.18. Outcome 8: Proportion of participants without improvement of hepatocyte ballooning: sensitivity analysis fixed-effect model",18,NA,22,27,11,13,0,0,0,0,0,0.149678062532632,0.962963,0.718131,1.291266,0.0224035224035223,24.264358,"18::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Chan 2017",2017,"Analysis 1.19. Outcome 9: Proportion of participants without improvement of NAS",19,NA,23,49,23,50,0,0,0,0,0,0,1.020408,0.668539,1.557476,0,30.039571,"19::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Navarro 2019",2019,"Analysis 1.19. Outcome 9: Proportion of participants without improvement of NAS",19,NA,18,26,9,12,0,0,0,0,0,0,0.923077,0.609436,1.39813,0,31.161952,"19::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Navarro 2019",2019,"Analysis 1.19. Outcome 9: Proportion of participants without improvement of NAS",19,NA,20,27,10,13,0,0,0,0,0,0.189841739456543,0.962963,0.663768,1.397022,0.036039886039886,38.798477,"19::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Chan 2017",2017,"Analysis 1.20. Outcome 9: Proportion of participants without improvement of NAS: sensitivity analysis fixed-effect model",20,NA,23,49,23,50,0,0,0,0,0,0,1.020408,0.668539,1.557476,0,46.863014,"20::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Navarro 2019",2019,"Analysis 1.20. Outcome 9: Proportion of participants without improvement of NAS: sensitivity analysis fixed-effect model",20,NA,18,26,9,12,0,0,0,0,0,0,0.923077,0.609436,1.39813,0,25.349755,"20::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Navarro 2019",2019,"Analysis 1.20. Outcome 9: Proportion of participants without improvement of NAS: sensitivity analysis fixed-effect model",20,NA,20,27,10,13,0,0,0,0,0,0.189841739456543,0.962963,0.663768,1.397022,0.036039886039886,27.787231,"20::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Chan 2017",2017,"Analysis 1.21. Outcome 10: Proportion of participants without improvement of fibrosis",21,NA,38,49,47,50,0,0,0,0,0,0,0.825011,0.698734,0.974108,0,49.648776,"21::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Navarro 2019",2019,"Analysis 1.21. Outcome 10: Proportion of participants without improvement of fibrosis",21,NA,20,27,9,13,0,0,0,0,0,0.217142803590165,1.069959,0.699093,1.637568,0.0471509971509971,22.425458,"21::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Navarro 2019",2019,"Analysis 1.21. Outcome 10: Proportion of participants without improvement of fibrosis",21,NA,23,26,9,12,0,0,0,0,0,0.181092518304331,1.179487,0.827079,1.682052,0.0327945001858045,27.925766,"21::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Chan 2017",2017,"Analysis 1.22. Outcome 10: Proportion of participants without improvement of fibrosis: sensitivity analysis fixed-effect model",22,NA,38,49,47,50,0,0,0,0,0,0,0.825011,0.698734,0.974108,0,65.536793,"22::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Navarro 2019",2019,"Analysis 1.22. Outcome 10: Proportion of participants without improvement of fibrosis: sensitivity analysis fixed-effect model",22,NA,23,26,9,12,0,0,0,0,0,0,1.179487,0.827079,1.682052,0,17.348371,"22::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Navarro 2019",2019,"Analysis 1.22. Outcome 10: Proportion of participants without improvement of fibrosis: sensitivity analysis fixed-effect model",22,NA,20,27,9,13,0,0,0,0,0,0.217142803590165,1.069959,0.699093,1.637568,0.0471509971509971,17.114835,"22::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Navarro 2019",2019,"Analysis 1.23. Outcome 11: Proportion of participants without normalisation of ALT",23,NA,21,27,12,13,0,0,0,0,0,0.13035438999998,0.842593,0.652619,1.087866,0.0169922669922669,28.749055,"23::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Navarro 2019",2019,"Analysis 1.23. Outcome 11: Proportion of participants without normalisation of ALT",23,NA,24,26,12,12,0,0,0,0,0,0,0.943704,0.802332,1.109985,0,71.250945,"23::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Navarro 2019",2019,"Analysis 1.24. Outcome 12: Proportion of participants without normalisation of AST",24,NA,22,26,9,12,0,0,0,0,0,0,1.128205,0.782826,1.625964,0,50.896123,"24::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Navarro 2019",2019,"Analysis 1.24. Outcome 12: Proportion of participants without normalisation of AST",24,NA,20,27,10,13,0,0,0,0,0,0.189841739456543,0.962963,0.663768,1.397022,0.036039886039886,49.103877,"24::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Chan 2017",2017,"Analysis 1.25. Outcome 13: Proportion of participants without improvement of LSM",25,NA,37,49,49,50,0,0,0,0,0,0,0.770512,0.653771,0.9081,0,100,"25::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Atarodi 2022",2022,"Analysis 1.26. Outcome 14: TC (mmol/L)",26,NA,0,30,0,30,5.3,0.81,5.07,0.81,0,0.210936336203686,0.23,-0.179909,0.639909,0.0444941379310344,52.552021,"26::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Rajendra 2022",2022,"Analysis 1.26. Outcome 14: TC (mmol/L)",26,NA,0,15,0,30,4.36,0.68,4.71,0.95,0,0,-0.35,-0.833718,0.133718,0,47.447979,"26::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Atarodi 2022",2022,"Analysis 1.27. Outcome 14: TC (mmol/L): sensitivity analysis fixed-effect model",27,NA,0,30,0,30,5.3,0.81,5.07,0.81,0,0.210936336203686,0.23,-0.179909,0.639909,0.0444941379310344,58.203536,"27::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Rajendra 2022",2022,"Analysis 1.27. Outcome 14: TC (mmol/L): sensitivity analysis fixed-effect model",27,NA,0,15,0,30,4.36,0.68,4.71,0.95,0,0,-0.35,-0.833718,0.133718,0,41.796464,"27::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Atarodi 2022",2022,"Analysis 1.28. Outcome 15: TG (mmol/L)",28,NA,0,30,0,30,1.63,0.5,1.9,0.91,0,0.192063806447562,-0.27,-0.64155,0.10155,0.0368885057471264,42.356841,"28::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Rajendra 2022",2022,"Analysis 1.28. Outcome 15: TG (mmol/L)",28,NA,0,15,0,30,1.4,0.37,1.75,0.72,0,0,-0.35,-0.668497,-0.031503,0,57.643159,"28::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Atarodi 2022",2022,"Analysis 1.29. Outcome 15: TG (mmol/L): sensitivity analysis fixed-effect model",29,NA,0,30,0,30,1.63,0.5,1.9,0.91,0,0.192063806447562,-0.27,-0.64155,0.10155,0.0368885057471264,42.356841,"29::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Rajendra 2022",2022,"Analysis 1.29. Outcome 15: TG (mmol/L): sensitivity analysis fixed-effect model",29,NA,0,15,0,30,1.4,0.37,1.75,0.72,0,0,-0.35,-0.668497,-0.031503,0,57.643159,"29::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Atarodi 2022",2022,"Analysis 1.30. Outcome 16: HDL cholesterol (mmol/L)",30,NA,0,30,0,30,1.18,0.15,1.21,0.37,0,0.073964110588666,-0.03,-0.172867,0.112867,0.0054706896551724,20.140281,"30::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Rajendra 2022",2022,"Analysis 1.30. Outcome 16: HDL cholesterol (mmol/L)",30,NA,0,15,0,30,1.08,0.13,1.08,0.08,0,0,0,-0.071746,0.071746,0,79.859719,"30::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Atarodi 2022",2022,"Analysis 1.31. Outcome 16: HDL cholesterol (mmol/L): sensitivity analysis fixed-effect model",31,NA,0,30,0,30,1.18,0.15,1.21,0.37,0,0.073964110588666,-0.03,-0.172867,0.112867,0.0054706896551724,20.140281,"31::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Rajendra 2022",2022,"Analysis 1.31. Outcome 16: HDL cholesterol (mmol/L): sensitivity analysis fixed-effect model",31,NA,0,15,0,30,1.08,0.13,1.08,0.08,0,0,0,-0.071746,0.071746,0,79.859719,"31::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Atarodi 2022",2022,"Analysis 1.32. Outcome 17: LDL cholesterol (mmol/L)",32,NA,0,30,0,30,3.36,0.4,3.19,0.51,0,0.119592219021869,0.17,-0.061934,0.401934,0.0143022988505747,62.159474,"32::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Rajendra 2022",2022,"Analysis 1.32. Outcome 17: LDL cholesterol (mmol/L)",32,NA,0,15,0,30,2.64,0.59,2.8,0.72,0,0,-0.16,-0.55437,0.23437,0,37.840526,"32::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Atarodi 2022",2022,"Analysis 1.33. Outcome 17: LDL cholesterol (mmol/L): sensitivity analysis fixed-effect model",33,NA,0,30,0,30,3.36,0.4,3.19,0.51,0,0.119592219021869,0.17,-0.061934,0.401934,0.0143022988505747,74.301095,"33::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Rajendra 2022",2022,"Analysis 1.33. Outcome 17: LDL cholesterol (mmol/L): sensitivity analysis fixed-effect model",33,NA,0,15,0,30,2.64,0.59,2.8,0.72,0,0,-0.16,-0.55437,0.23437,0,25.698905,"33::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Atarodi 2022",2022,"Analysis 1.34. Outcome 18: FBS (mmol/L)",34,NA,0,30,0,30,6.26,1.16,6.36,2.12,0,0.447026446284961,-0.1,-0.964757,0.764757,0.199832643678161,100,"34::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Atarodi 2022",2022,"Analysis 1.35. Outcome 19: BMI (kg/m2)",35,NA,0,30,0,30,46,4.5,45.1,4.9,0,1.22594087723787,0.9,-1.480637,3.280637,1.50293103448276,13.863089,"35::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Masoodi 2013",2013,"Analysis 1.35. Outcome 19: BMI (kg/m2)",35,NA,0,50,0,50,28.7,2.56,28.84,2.89,0,0,-0.14,-1.210137,0.930137,0,68.606897,"35::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mirhashemi 2022",2022,"Analysis 1.35. Outcome 19: BMI (kg/m2)",35,NA,0,30,0,30,45.01,4.44,46.32,3.91,0,1.12634097856733,-1.31,-3.427054,0.807054,1.268644,17.530014,"35::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Atarodi 2022",2022,"Analysis 1.36. Outcome 19: BMI (kg/m2): sensitivity analysis fixed-effect model",36,NA,0,30,0,30,46,4.5,45.1,4.9,0,1.22594087723787,0.9,-1.480637,3.280637,1.50293103448276,13.863089,"36::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Masoodi 2013",2013,"Analysis 1.36. Outcome 19: BMI (kg/m2): sensitivity analysis fixed-effect model",36,NA,0,50,0,50,28.7,2.56,28.84,2.89,0,0,-0.14,-1.210137,0.930137,0,68.606897,"36::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mirhashemi 2022",2022,"Analysis 1.36. Outcome 19: BMI (kg/m2): sensitivity analysis fixed-effect model",36,NA,0,30,0,30,45.01,4.44,46.32,3.91,0,1.12634097856733,-1.31,-3.427054,0.807054,1.268644,17.530014,"36::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Rajendra 2022",2022,"Analysis 2.1. Outcome 1: Proportion of participants with serious adverse events",1,NA,0,15,0,30,0,0,0,0,0,0,NA,NA,NA,0,NA,"1::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Hajiaghamohammadi 2012",2012,"Analysis 2.2. Outcome 2: ALT (U/L)",2,NA,0,11,0,22,53.05,13.99,60.95,14.21,0,5.19337121198307,-7.9,-18.078821,2.278821,26.9711045454546,7.967158,"2::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Hajiaghamohammadi 2012",2012,"Analysis 2.2. Outcome 2: ALT (U/L)",2,NA,0,11,0,22,53.05,13.99,52.27,14.53,0,4.30032239806189,0.78,-9.4774,11.0374,18.4927727272727,7.846748,"2::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Rajendra 2022",2022,"Analysis 2.2. Outcome 2: ALT (U/L)",2,NA,0,15,0,30,14.86,4.62,15.24,5.15,0,0,-0.38,-3.35698,2.59698,0,84.186093,"2::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Hajiaghamohammadi 2012",2012,"Analysis 2.3. Outcome 2: ALT (U/L): sensitivity analysis fixed-effect model",3,NA,0,11,0,22,53.05,13.99,60.95,14.21,0,5.19337121198307,-7.9,-18.078821,2.278821,26.9711045454546,7.312345,"3::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Hajiaghamohammadi 2012",2012,"Analysis 2.3. Outcome 2: ALT (U/L): sensitivity analysis fixed-effect model",3,NA,0,11,0,22,53.05,13.99,52.27,14.53,0,4.30032239806189,0.78,-9.4774,11.0374,18.4927727272727,7.200738,"3::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Rajendra 2022",2022,"Analysis 2.3. Outcome 2: ALT (U/L): sensitivity analysis fixed-effect model",3,NA,0,15,0,30,14.86,4.62,15.24,5.15,0,0,-0.38,-3.35698,2.59698,0,85.486917,"3::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Hajiaghamohammadi 2012",2012,"Analysis 2.4. Outcome 3: AST (U/L)",4,NA,0,11,0,22,37.77,8.78,42.5,10.02,0,3.40171881687639,-4.73,-11.397246,1.937246,11.5716909090909,24.210098,"4::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Hajiaghamohammadi 2012",2012,"Analysis 2.4. Outcome 3: AST (U/L)",4,NA,0,11,0,22,37.77,8.78,37.59,8.67,0,2.63073874864768,0.18,-6.148227,6.508227,6.92078636363636,25.909603,"4::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Rajendra 2022",2022,"Analysis 2.4. Outcome 3: AST (U/L)",4,NA,0,15,0,30,24.38,4.77,22,5.63,0,0,2.38,-0.764153,5.524153,0,49.8803,"4::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Hajiaghamohammadi 2012",2012,"Analysis 2.5. Outcome 3: AST (U/L): sensitivity analysis fixed-effect model",5,NA,0,11,0,22,37.77,8.78,37.59,8.67,0,2.63073874864768,0.18,-6.148227,6.508227,6.92078636363636,16.801536,"5::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Hajiaghamohammadi 2012",2012,"Analysis 2.5. Outcome 3: AST (U/L): sensitivity analysis fixed-effect model",5,NA,0,11,0,22,37.77,8.78,42.5,10.02,0,3.40171881687639,-4.73,-11.397246,1.937246,11.5716909090909,15.136312,"5::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Rajendra 2022",2022,"Analysis 2.5. Outcome 3: AST (U/L): sensitivity analysis fixed-effect model",5,NA,0,15,0,30,24.38,4.77,22,5.63,0,0,2.38,-0.764153,5.524153,0,68.062152,"5::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Rajendra 2022",2022,"Analysis 2.6. Outcome 4: GGT (U/L)",6,NA,0,15,0,30,24.52,5.73,21.73,6.99,0,0,2.79,-1.039476,6.619476,0,100,"6::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Rajendra 2022",2022,"Analysis 2.7. Outcome 5: Proportion of participants with non-serious adverse events",7,NA,1,15,3,30,0,0,0,0,0,0,0.666667,0.075614,5.877806,0,100,"7::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Hajiaghamohammadi 2012",2012,"Analysis 2.8. Outcome 6: TC (mmol/L) ",8,NA,0,11,0,22,4.69,0.84,4.54,0.83,0,0.308964546362671,0.15,-0.455559,0.755559,0.0954590909090909,20.962559,"8::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Hajiaghamohammadi 2012",2012,"Analysis 2.8. Outcome 6: TC (mmol/L) ",8,NA,0,11,0,22,4.69,0.84,4.62,0.83,0,0,0.07,-0.535559,0.675559,0,20.962559,"8::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Rajendra 2022",2022,"Analysis 2.8. Outcome 6: TC (mmol/L) ",8,NA,0,15,0,30,4.36,0.68,4.23,0.33,0,0,0.13,-0.233818,0.493818,0,58.074882,"8::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Hajiaghamohammadi 2012",2012,"Analysis 2.9. Outcome 6: TC (mmol/L): sensitivity analysis fixed-effect model",9,NA,0,11,0,22,4.69,0.84,4.62,0.83,0,0,0.07,-0.535559,0.675559,0,20.962559,"9::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Hajiaghamohammadi 2012",2012,"Analysis 2.9. Outcome 6: TC (mmol/L): sensitivity analysis fixed-effect model",9,NA,0,11,0,22,4.69,0.84,4.54,0.83,0,0.308964546362671,0.15,-0.455559,0.755559,0.0954590909090909,20.962559,"9::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Rajendra 2022",2022,"Analysis 2.9. Outcome 6: TC (mmol/L): sensitivity analysis fixed-effect model",9,NA,0,15,0,30,4.36,0.68,4.23,0.33,0,0,0.13,-0.233818,0.493818,0,58.074882,"9::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Hajiaghamohammadi 2012",2012,"Analysis 2.10. Outcome 7: TG (mmol/L) ",10,NA,0,11,0,22,2.7,0.6,2.53,0.53,0,0.170680456355782,0.17,-0.248054,0.588054,0.0291318181818181,19.15139,"10::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Hajiaghamohammadi 2012",2012,"Analysis 2.10. Outcome 7: TG (mmol/L) ",10,NA,0,11,0,22,2.7,0.6,2.51,0.57,0,0.217934518939645,0.19,-0.237144,0.617144,0.0474954545454545,18.344938,"10::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Rajendra 2022",2022,"Analysis 2.10. Outcome 7: TG (mmol/L) ",10,NA,0,15,0,30,1.4,0.37,1.49,0.38,0,0,-0.09,-0.321409,0.141409,0,62.503672,"10::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Hajiaghamohammadi 2012",2012,"Analysis 2.11. Outcome 7: TG (mmol/L): sensitivity analysis fixed-effect model",11,NA,0,11,0,22,2.7,0.6,2.53,0.53,0,0.170680456355782,0.17,-0.248054,0.588054,0.0291318181818181,19.15139,"11::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Hajiaghamohammadi 2012",2012,"Analysis 2.11. Outcome 7: TG (mmol/L): sensitivity analysis fixed-effect model",11,NA,0,11,0,22,2.7,0.6,2.51,0.57,0,0.217934518939645,0.19,-0.237144,0.617144,0.0474954545454545,18.344938,"11::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Rajendra 2022",2022,"Analysis 2.11. Outcome 7: TG (mmol/L): sensitivity analysis fixed-effect model",11,NA,0,15,0,30,1.4,0.37,1.49,0.38,0,0,-0.09,-0.321409,0.141409,0,62.503672,"11::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Rajendra 2022",2022,"Analysis 2.12. Outcome 8: HDL cholesterol (mmol/L) ",12,NA,0,15,0,30,1.08,0.13,1.12,0.11,0,0,-0.04,-0.116664,0.036664,0,100,"12::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Rajendra 2022",2022,"Analysis 2.13. Outcome 9: LDL cholesterol (mmol/L) ",13,NA,0,15,0,30,2.64,0.59,2.43,0.26,0,0,0.21,-0.102736,0.522736,0,100,"13::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Hajiaghamohammadi 2012",2012,"Analysis 2.14. Outcome 10: FBS (mmol/L) ",14,NA,0,11,0,22,5.22,0.32,4.72,0.29,0,0.092072106130319,0.5,0.2754,0.7246,0.0084772727272727,50,"14::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Hajiaghamohammadi 2012",2012,"Analysis 2.14. Outcome 10: FBS (mmol/L) ",14,NA,0,11,0,22,5.22,0.32,4.86,0.29,0,0.114594145495388,0.36,0.1354,0.5846,0.0131318181818181,50,"14::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Hajiaghamohammadi 2012",2012,"Analysis 2.15. Outcome 11: HOMA-IR",15,NA,0,11,0,22,2.7,0.85,2.12,0.67,0,0.230749766078873,0.58,0.004937,1.155063,0.0532454545454545,51.831222,"15::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Hajiaghamohammadi 2012",2012,"Analysis 2.15. Outcome 11: HOMA-IR",15,NA,0,11,0,22,2.7,0.85,2.24,0.77,0,0.304354757120401,0.46,-0.136524,1.056524,0.0926318181818181,48.168778,"15::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Hajiaghamohammadi 2012",2012,"Analysis 2.16. Outcome 12: Insulin (mmol/l)",16,NA,0,11,0,22,13.5,3.7,11.76,3.26,0,1.05135410521168,1.74,-0.836155,4.316155,1.10534545454545,51.354942,"16::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Hajiaghamohammadi 2012",2012,"Analysis 2.16. Outcome 12: Insulin (mmol/l)",16,NA,0,11,0,22,13.5,3.7,12.06,3.57,0,1.35050327319451,1.44,-1.206938,4.086938,1.82385909090909,48.645058,"16::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Hajiaghamohammadi 2012",2012,"Analysis 2.17. Outcome 13: Weight (kg)",17,NA,0,11,0,22,77.09,9.5,75.46,9.9,0,3.55802549942316,1.63,-5.343602,8.603602,12.6595454545455,48.978919,"17::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Hajiaghamohammadi 2012",2012,"Analysis 2.17. Outcome 13: Weight (kg)",17,NA,0,11,0,22,77.09,9.5,77.82,9.32,0,3.48609184670117,-0.73,-7.562614,6.102614,12.1528363636364,51.021081,"17::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Hajiaghamohammadi 2012",2012,"Analysis 2.18. Outcome 14: BMI (kg/m2)",18,NA,0,11,0,22,27.48,1.7,27,1.98,0,0.664023548322853,0.48,-0.821462,1.781462,0.440927272727273,47.884577,"18::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Hajiaghamohammadi 2012",2012,"Analysis 2.18. Outcome 14: BMI (kg/m2)",18,NA,0,11,0,22,27.48,1.7,27.67,1.77,0,0,-0.19,-1.437516,1.057516,0,52.115423,"18::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Aller 2015",2015,"Analysis 3.1. Outcome 1: Proportion of participants with serious adverse events",1,NA,0,18,0,18,0,0,0,0,0,0,NA,NA,NA,0,NA,"1::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Loguercio 2012",2012,"Analysis 3.1. Outcome 1: Proportion of participants with serious adverse events",1,NA,0,73,0,70,0,0,0,0,0,0,NA,NA,NA,0,NA,"1::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Aller 2015",2015,"Analysis 3.2. Outcome 1: Proportion of participants with serious adverse events: sensitivity analysis 'best-worst' case scenario",2,NA,0,18,0,18,0,0,0,0,0,0,NA,NA,NA,0,NA,"2::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Loguercio 2012",2012,"Analysis 3.2. Outcome 1: Proportion of participants with serious adverse events: sensitivity analysis 'best-worst' case scenario",2,NA,0,73,17,70,0,0,0,0,0,1.42353645316806,0.100032,0.036452,0.274511,2.02645603349829,100,"2::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Aller 2015",2015,"Analysis 3.3. Outcome 1: Proportion of participants with serious adverse events: sensitivity analysis 'worst-best' case scenario",3,NA,0,18,0,18,0,0,0,0,0,0,NA,NA,NA,0,NA,"3::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Loguercio 2012",2012,"Analysis 3.3. Outcome 1: Proportion of participants with serious adverse events: sensitivity analysis 'worst-best' case scenario",3,NA,16,73,0,70,0,0,0,0,0,0.395654807477064,8.937633,3.170225,25.197354,6.388032336028,100,"3::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Aller 2015",2015,"Analysis 3.4. Outcome 2: ALT (U/L)",4,NA,0,18,0,18,52.7,26,54.7,18,0,7.4535599249993,-2,-16.608709,12.608709,55.5555555555556,16.417929,"4::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Ataee 2021",2021,"Analysis 3.4. Outcome 2: ALT (U/L)",4,NA,0,30,0,30,42.56,27.92,39.07,21.78,0,0,3.49,-9.181208,16.161208,0,19.92588,"4::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Dallio 2021",2021,"Analysis 3.4. Outcome 2: ALT (U/L)",4,NA,0,30,0,15,34,14,56,37,0,9.88938825206089,-22,-41.382845,-2.617155,97.8,10.657352,"4::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Dallio 2021",2021,"Analysis 3.4. Outcome 2: ALT (U/L)",4,NA,0,32,0,15,68,43,56,37,0,11.013533341606,12,-11.928256,35.928256,121.297916666667,7.475425,"4::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Li 2024",2024,"Analysis 3.4. Outcome 2: ALT (U/L)",4,NA,0,60,0,61,27.14,12.75,27.19,13.25,0,0,-0.05,-4.682921,4.582921,0,45.523415,"4::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Aller 2015",2015,"Analysis 3.5. Outcome 2: ALT (U/L): sensitivity analysis fixed-effect model",5,NA,0,18,0,18,52.7,26,54.7,18,0,7.4535599249993,-2,-16.608709,12.608709,55.5555555555556,7.568361,"5::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Ataee 2021",2021,"Analysis 3.5. Outcome 2: ALT (U/L): sensitivity analysis fixed-effect model",5,NA,0,30,0,30,42.56,27.92,39.07,21.78,0,0,3.49,-9.181208,16.161208,0,10.059803,"5::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Dallio 2021",2021,"Analysis 3.5. Outcome 2: ALT (U/L): sensitivity analysis fixed-effect model",5,NA,0,30,0,15,34,14,56,37,0,5.56594663150501,-22,-41.382845,-2.617155,30.9797619047619,4.299228,"5::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Dallio 2021",2021,"Analysis 3.5. Outcome 2: ALT (U/L): sensitivity analysis fixed-effect model",5,NA,0,32,0,15,68,43,56,37,0,12.2085182011031,12,-11.928256,35.928256,149.047916666667,2.821002,"5::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Li 2024",2024,"Analysis 3.5. Outcome 2: ALT (U/L): sensitivity analysis fixed-effect model",5,NA,0,60,0,61,27.14,12.75,27.19,13.25,0,2.36377849437967,-0.05,-4.682921,4.582921,5.5874487704918,75.251606,"5::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Aller 2015",2015,"Analysis 3.6. Outcome 3: AST (U/L)",6,NA,0,18,0,18,34.6,16,36,11.8,0,0,-1.4,-10.58422,7.78422,0,4.142169,"6::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Ataee 2021",2021,"Analysis 3.6. Outcome 3: AST (U/L)",6,NA,0,30,0,30,34.04,15.01,27.57,13.91,0,0,6.47,-0.852927,13.792927,0,6.51543,"6::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Dallio 2021",2021,"Analysis 3.6. Outcome 3: AST (U/L)",6,NA,0,30,0,15,34,14,29,16,0,4.85798312059645,5,-4.521472,14.521472,23.6,3.853934,"6::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Dallio 2021",2021,"Analysis 3.6. Outcome 3: AST (U/L)",6,NA,0,32,0,15,34,31,29,16,0,6.86279219171517,5,-8.450826,18.450826,47.0979166666667,1.931143,"6::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Li 2024",2024,"Analysis 3.6. Outcome 3: AST (U/L)",6,NA,0,60,0,61,21.99,5.99,21.77,5.47,0,0,0.22,-1.824862,2.264862,0,83.557324,"6::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Aller 2015",2015,"Analysis 3.7. Outcome 3: AST (U/L): sensitivity analysis fixed-effect model",7,NA,0,18,0,18,34.6,16,36,11.8,0,0,-1.4,-10.58422,7.78422,0,4.142169,"7::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Ataee 2021",2021,"Analysis 3.7. Outcome 3: AST (U/L): sensitivity analysis fixed-effect model",7,NA,0,30,0,30,34.04,15.01,27.57,13.91,0,0,6.47,-0.852927,13.792927,0,6.51543,"7::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Dallio 2021",2021,"Analysis 3.7. Outcome 3: AST (U/L): sensitivity analysis fixed-effect model",7,NA,0,30,0,15,34,14,29,16,0,4.85798312059645,5,-4.521472,14.521472,23.6,3.853934,"7::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Dallio 2021",2021,"Analysis 3.7. Outcome 3: AST (U/L): sensitivity analysis fixed-effect model",7,NA,0,32,0,15,34,31,29,16,0,6.86279219171517,5,-8.450826,18.450826,47.0979166666667,1.931143,"7::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Li 2024",2024,"Analysis 3.7. Outcome 3: AST (U/L): sensitivity analysis fixed-effect model",7,NA,0,60,0,61,21.99,5.99,21.77,5.47,0,1.04331597516942,0.22,-1.824862,2.264862,1.08850822404372,83.557324,"7::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Aller 2015",2015,"Analysis 3.8. Outcome 4: GGT (U/L)",8,NA,0,18,0,18,46.2,27,50.3,27,0,0,-4.1,-21.739676,13.539676,0,9.9268,"8::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Dallio 2021",2021,"Analysis 3.8. Outcome 4: GGT (U/L)",8,NA,0,32,0,15,64,68,58,61,0,0,6,-32.833345,44.833345,0,2.04824,"8::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Dallio 2021",2021,"Analysis 3.8. Outcome 4: GGT (U/L)",8,NA,0,30,0,15,57,30,58,61,0,0,-1,-33.683048,31.683048,0,2.891648,"8::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Li 2024",2024,"Analysis 3.8. Outcome 4: GGT (U/L)",8,NA,0,60,0,61,33.13,14.85,34.18,18.76,0,0,-1.05,-7.073452,4.973452,0,85.133312,"8::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Aller 2015",2015,"Analysis 3.9. Outcome 4: GGT (U/L): sensitivity analysis fixed-effect model",9,NA,0,18,0,18,46.2,27,50.3,27,0,0,-4.1,-21.739676,13.539676,0,9.9268,"9::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Dallio 2021",2021,"Analysis 3.9. Outcome 4: GGT (U/L): sensitivity analysis fixed-effect model",9,NA,0,30,0,15,57,30,58,61,0,16.6190152135037,-1,-33.683048,31.683048,276.191666666667,2.891648,"9::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Dallio 2021",2021,"Analysis 3.9. Outcome 4: GGT (U/L): sensitivity analysis fixed-effect model",9,NA,0,32,0,15,64,68,58,61,0,19.8132951996044,6,-32.833345,44.833345,392.566666666667,2.04824,"9::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Li 2024",2024,"Analysis 3.9. Outcome 4: GGT (U/L): sensitivity analysis fixed-effect model",9,NA,0,60,0,61,33.13,14.85,34.18,18.76,0,0,-1.05,-7.073452,4.973452,0,85.133312,"9::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Aller 2015",2015,"Analysis 3.10. Outcome 5: Proportion of participants with non-serious adverse events",10,NA,0,18,0,18,0,0,0,0,0,0,NA,NA,NA,0,NA,"10::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Li 2024",2024,"Analysis 3.10. Outcome 5: Proportion of participants with non-serious adverse events",10,NA,15,60,21,61,0,0,0,0,0,0.293663304354524,0.72619,0.415391,1.269533,0.0862381363244176,100,"10::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Loguercio 2012",2012,"Analysis 3.11. Outcome 6: Proportion of participants without normalisation of ALT",11,NA,32,73,50,70,0,0,0,0,0,0.136687400058351,0.613699,0.455114,0.827541,0.0186834453347118,100,"11::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Loguercio 2012",2012,"Analysis 3.12. Outcome 7: Proportion of participants without normalisation of AST",12,NA,31,73,45,70,0,0,0,0,0,0.148032874973984,0.660578,0.480142,0.908823,0.021913732073063,100,"12::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Loguercio 2012",2012,"Analysis 3.13. Outcome 8: Proportion of participants without improvement of the ultrasound",13,NA,32,73,38,70,0,0,0,0,0,0.158111463241588,0.807498,0.576423,1.131207,0.024999234808396,100,"13::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Ataee 2021",2021,"Analysis 3.14. Outcome 9: TC (mmol/L)",14,NA,0,30,0,30,4.54,1.11,4.64,0.86,0,0,-0.1,-0.602467,0.402467,0,32.802545,"14::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Li 2024",2024,"Analysis 3.14. Outcome 9: TC (mmol/L)",14,NA,0,60,0,61,5.29,0.96,5.3,1.01,0,0.179117142729757,-0.01,-0.361063,0.341063,0.0320829508196721,67.197455,"14::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Ataee 2021",2021,"Analysis 3.15. Outcome 9: TC (mmol/L): sensitivity analysis fixed-effect model",15,NA,0,30,0,30,4.54,1.11,4.64,0.86,0,0,-0.1,-0.602467,0.402467,0,32.802545,"15::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Li 2024",2024,"Analysis 3.15. Outcome 9: TC (mmol/L): sensitivity analysis fixed-effect model",15,NA,0,60,0,61,5.29,0.96,5.3,1.01,0,0.154461518365377,-0.01,-0.361063,0.341063,0.0238583606557377,67.197455,"15::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Aller 2015",2015,"Analysis 3.16. Outcome 10: TG (mmol/L)",16,NA,0,18,0,18,2.1,1,1.9,0.7,0,0.738617326872011,0.2,-0.363904,0.763904,0.545555555555555,13.657638,"16::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Ataee 2021",2021,"Analysis 3.16. Outcome 10: TG (mmol/L)",16,NA,0,30,0,30,2.13,1.02,1.65,0.79,0,0,0.48,0.018332,0.941668,0,20.37637,"16::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Li 2024",2024,"Analysis 3.16. Outcome 10: TG (mmol/L)",16,NA,0,60,0,61,1.95,0.72,1.82,0.72,0,0.130913561771643,0.13,-0.126586,0.386586,0.0171383606557377,65.965991,"16::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Aller 2015",2015,"Analysis 3.17. Outcome 10: TG (mmol/L): sensitivity analysis fixed-effect model",17,NA,0,18,0,18,2.1,1,1.9,0.7,0,0.738617326872011,0.2,-0.363904,0.763904,0.545555555555555,13.657638,"17::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Ataee 2021",2021,"Analysis 3.17. Outcome 10: TG (mmol/L): sensitivity analysis fixed-effect model",17,NA,0,30,0,30,2.13,1.02,1.65,0.79,0,0,0.48,0.018332,0.941668,0,20.37637,"17::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Li 2024",2024,"Analysis 3.17. Outcome 10: TG (mmol/L): sensitivity analysis fixed-effect model",17,NA,0,60,0,61,1.95,0.72,1.82,0.72,0,0.130913561771643,0.13,-0.126586,0.386586,0.0171383606557377,65.965991,"17::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Ataee 2021",2021,"Analysis 3.18. Outcome 11: HDL cholesterol (mmol/L)",18,NA,0,30,0,30,1.05,0.31,1.11,0.18,0,0,-0.06,-0.188274,0.068274,0,28.992341,"18::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Li 2024",2024,"Analysis 3.18. Outcome 11: HDL cholesterol (mmol/L)",18,NA,0,60,0,61,1.18,0.23,1.25,0.23,0,0,-0.07,-0.151965,0.011965,0,71.007659,"18::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Ataee 2021",2021,"Analysis 3.19. Outcome 11: HDL cholesterol (mmol/L): sensitivity analysis fixed-effect model",19,NA,0,30,0,30,1.05,0.31,1.11,0.18,0,0,-0.06,-0.188274,0.068274,0,28.992341,"19::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Li 2024",2024,"Analysis 3.19. Outcome 11: HDL cholesterol (mmol/L): sensitivity analysis fixed-effect model",19,NA,0,60,0,61,1.18,0.23,1.25,0.23,0,0.0418196100103858,-0.07,-0.151965,0.011965,0.0017488797814207,71.007659,"19::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Ataee 2021",2021,"Analysis 3.20. Outcome 12: LDL cholesterol (mmol/L)",20,NA,0,30,0,30,2.81,1.08,3,0.76,0,0,-0.19,-0.662564,0.282564,0,31.12987,"20::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Li 2024",2024,"Analysis 3.20. Outcome 12: LDL cholesterol (mmol/L)",20,NA,0,60,0,61,3.36,0.83,3.35,0.95,0,0,0.01,-0.307712,0.327712,0,68.87013,"20::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Ataee 2021",2021,"Analysis 3.21. Outcome 12: LDL cholesterol (mmol/L): sensitivity analysis fixed-effect model",21,NA,0,30,0,30,2.81,1.08,3,0.76,0,0,-0.19,-0.662564,0.282564,0,31.12987,"21::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Li 2024",2024,"Analysis 3.21. Outcome 12: LDL cholesterol (mmol/L): sensitivity analysis fixed-effect model",21,NA,0,60,0,61,3.36,0.83,3.35,0.95,0,0.162101044518164,0.01,-0.307712,0.327712,0.0262767486338797,68.87013,"21::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Aller 2015",2015,"Analysis 3.22. Outcome 13: FBS (mmol/L)",22,NA,0,18,0,18,5.2,0.7,6.4,2.6,0,0,-1.2,-2.443887,0.043887,0,6.419593,"22::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Ataee 2021",2021,"Analysis 3.22. Outcome 13: FBS (mmol/L)",22,NA,0,30,0,30,5.36,0.67,5.52,0.69,0,0,-0.16,-0.504158,0.184158,0,26.793276,"22::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Dallio 2021",2021,"Analysis 3.22. Outcome 13: FBS (mmol/L)",22,NA,0,30,0,15,5,1,5.6,0.8,0,0,-0.6,-1.140325,-0.059675,0,19.33986,"22::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Dallio 2021",2021,"Analysis 3.22. Outcome 13: FBS (mmol/L)",22,NA,0,32,0,15,6.2,1.5,5.6,0.8,0,0,0.6,-0.05879,1.25879,0,15.75221,"22::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Li 2024",2024,"Analysis 3.22. Outcome 13: FBS (mmol/L)",22,NA,0,60,0,61,5.9,0.62,5.95,0.62,0,0,-0.05,-0.270949,0.170949,0,31.695061,"22::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Aller 2015",2015,"Analysis 3.23. Outcome 13: FBS (mmol/L): sensitivity analysis fixed-effect model",23,NA,0,18,0,18,5.2,0.7,6.4,2.6,0,0,-1.2,-2.443887,0.043887,0,1.830768,"23::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Ataee 2021",2021,"Analysis 3.23. Outcome 13: FBS (mmol/L): sensitivity analysis fixed-effect model",23,NA,0,30,0,30,5.36,0.67,5.52,0.69,0,0,-0.16,-0.504158,0.184158,0,23.915436,"23::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Dallio 2021",2021,"Analysis 3.23. Outcome 13: FBS (mmol/L): sensitivity analysis fixed-effect model",23,NA,0,30,0,15,5,1,5.6,0.8,0,0.275680975041804,-0.6,-1.140325,-0.059675,0.076,9.702534,"23::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Dallio 2021",2021,"Analysis 3.23. Outcome 13: FBS (mmol/L): sensitivity analysis fixed-effect model",23,NA,0,32,0,15,6.2,1.5,5.6,0.8,0,0.336123737136589,0.6,-0.05879,1.25879,0.112979166666667,6.526802,"23::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Li 2024",2024,"Analysis 3.23. Outcome 13: FBS (mmol/L): sensitivity analysis fixed-effect model",23,NA,0,60,0,61,5.9,0.62,5.95,0.62,0,0.112731122636692,-0.05,-0.270949,0.170949,0.0127083060109289,58.024461,"23::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Aller 2015",2015,"Analysis 3.24. Outcome 14: HOMA-IR",24,NA,0,18,0,18,3.4,2.2,4.9,4,0,0,-1.5,-3.608923,0.608923,0,15.554656,"24::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Dallio 2021",2021,"Analysis 3.24. Outcome 14: HOMA-IR",24,NA,0,30,0,15,4.51,3.13,6.33,2.71,0,0.755887998758193,-1.82,-3.590673,-0.049327,0.571366666666667,19.756262,"24::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Dallio 2021",2021,"Analysis 3.24. Outcome 14: HOMA-IR",24,NA,0,32,0,15,7.16,3.46,6.33,2.71,0,0.786712039651951,0.83,-0.991522,2.651522,0.618915833333333,19.040373,"24::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Li 2024",2024,"Analysis 3.24. Outcome 14: HOMA-IR",24,NA,0,60,0,61,3.9,1.48,4.17,1.95,0,0,-0.27,-0.886198,0.346198,0,45.648709,"24::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Aller 2015",2015,"Analysis 3.25. Outcome 14: HOMA-IR: sensitivity analysis fixed-effect model",25,NA,0,18,0,18,3.4,2.2,4.9,4,0,1.0760008261046,-1.5,-3.608923,0.608923,1.15777777777778,6.020354,"25::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Dallio 2021",2021,"Analysis 3.25. Outcome 14: HOMA-IR: sensitivity analysis fixed-effect model",25,NA,0,30,0,30,4.51,3.13,6.33,2.71,0,0,-1.82,-3.301513,-0.338487,0,12.199229,"25::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Dallio 2021",2021,"Analysis 3.25. Outcome 14: HOMA-IR: sensitivity analysis fixed-effect model",25,NA,0,32,0,30,7.16,3.46,6.33,2.71,0,0.786712039651951,0.83,-0.711927,2.371927,0.618915833333333,11.262004,"25::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Li 2024",2024,"Analysis 3.25. Outcome 14: HOMA-IR: sensitivity analysis fixed-effect model",25,NA,0,60,0,61,3.9,1.48,4.17,1.95,0,0.314392640245342,-0.27,-0.886198,0.346198,0.0988427322404371,70.518413,"25::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Dallio 2021",2021,"Analysis 3.26. Outcome 15: Insulin (pmol/L)",26,NA,0,30,0,15,175,44.8,175,62.51,0,0,0,-35.464049,35.464049,0,22.973241,"26::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Dallio 2021",2021,"Analysis 3.26. Outcome 15: Insulin (pmol/L)",26,NA,0,32,0,15,134.7,62.51,175,62.51,0,0,-40.3,-78.637686,-1.962314,0,20.440206,"26::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Li 2024",2024,"Analysis 3.26. Outcome 15: Insulin (pmol/L)",26,NA,0,60,0,61,103.69,39.73,108.55,47.16,0,0,-4.86,-20.388058,10.668058,0,56.586553,"26::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Dallio 2021",2021,"Analysis 3.27. Outcome 15: Insulin (pmol/L): sensitivity analysis fixed-effect model",27,NA,0,30,0,15,175,44.8,175,62.51,0,0,0,-35.464049,35.464049,0,14.140744,"27::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Dallio 2021",2021,"Analysis 3.27. Outcome 15: Insulin (pmol/L): sensitivity analysis fixed-effect model",27,NA,0,32,0,15,134.7,62.51,175,62.51,0,0,-40.3,-78.637686,-1.962314,0,12.100327,"27::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Li 2024",2024,"Analysis 3.27. Outcome 15: Insulin (pmol/L): sensitivity analysis fixed-effect model",27,NA,0,60,0,61,103.69,39.73,108.55,47.16,0,0,-4.86,-20.388058,10.668058,0,73.758929,"27::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Aller 2015",2015,"Analysis 3.28. Outcome 16: Weight (kg)",28,NA,0,18,0,18,89.5,13,87.4,13.9,0,0,2.1,-6.692089,10.892089,0,14.026498,"28::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Li 2024",2024,"Analysis 3.28. Outcome 16: Weight (kg)",28,NA,0,60,0,61,71.9,10.33,69.57,9.58,0,0,2.33,-1.221276,5.881276,0,85.973502,"28::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Aller 2015",2015,"Analysis 3.29. Outcome 16: Weight (kg): sensitivity analysis fixed-effect model",29,NA,0,18,0,18,89.5,13,87.4,13.9,0,0,2.1,-6.692089,10.892089,0,14.026498,"29::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Li 2024",2024,"Analysis 3.29. Outcome 16: Weight (kg): sensitivity analysis fixed-effect model",29,NA,0,60,0,61,71.9,10.33,69.57,9.58,0,1.81190861088733,2.33,-1.221276,5.881276,3.28301281420765,85.973502,"29::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Aller 2015",2015,"Analysis 3.30. Outcome 17: BMI (kg/m2)",30,NA,0,18,0,18,31.7,5.8,32.1,7.1,0,0,-0.4,-4.635266,3.835266,0,8.860327,"30::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Dallio 2021",2021,"Analysis 3.30. Outcome 17: BMI (kg/m2)",30,NA,0,32,0,15,29.07,3.1,28.1,2.7,0,0.886742634590218,0.97,-0.767984,2.707984,0.7863125,27.218593,"30::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Dallio 2021",2021,"Analysis 3.30. Outcome 17: BMI (kg/m2)",30,NA,0,30,0,15,31.6,3.6,28.1,2.7,0,1.03569622315941,3.5,1.622113,5.377887,1.07266666666667,25.431619,"30::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Li 2024",2024,"Analysis 3.30. Outcome 17: BMI (kg/m2)",30,NA,0,60,0,61,27.14,2.61,26.35,2.75,0,0,0.79,-0.165189,1.745189,0,38.489462,"30::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Aller 2015",2015,"Analysis 3.31. Outcome 17: BMI (kg/m2): sensitivity analysis fixed-effect model",31,NA,0,18,0,18,31.7,5.8,32.1,7.1,0,0,-0.4,-4.635266,3.835266,0,3.156077,"31::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Dallio 2021",2021,"Analysis 3.31. Outcome 17: BMI (kg/m2): sensitivity analysis fixed-effect model",31,NA,0,30,0,15,31.6,3.6,28.1,2.7,0,0,3.5,1.622113,5.377887,0,16.053514,"31::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Dallio 2021",2021,"Analysis 3.31. Outcome 17: BMI (kg/m2): sensitivity analysis fixed-effect model",31,NA,0,32,0,15,29.07,3.1,28.1,2.7,0,0,0.97,-0.767984,2.707984,0,18.742072,"31::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Li 2024",2024,"Analysis 3.31. Outcome 17: BMI (kg/m2): sensitivity analysis fixed-effect model",31,NA,0,60,0,61,27.14,2.61,26.35,2.75,0,0.487350397389871,0.79,-0.165189,1.745189,0.237510409836066,62.048337,"31::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Aller 2015",2015,"Analysis 3.32. Outcome 18: WC (cm)",32,NA,0,18,0,18,101.6,9.7,100.6,13,0,0,1,-6.493143,8.493143,0,9.091797,"32::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Li 2024",2024,"Analysis 3.32. Outcome 18: WC (cm)",32,NA,0,60,0,61,94.24,6.84,92.35,6.45,0,0,1.89,-0.479667,4.259667,0,90.908203,"32::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Aller 2015",2015,"Analysis 3.33. Outcome 18: WC (cm): sensitivity analysis fixed-effect model",33,NA,0,18,0,18,101.6,9.7,100.6,13,0,0,1,-6.493143,8.493143,0,9.091797,"33::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Li 2024",2024,"Analysis 3.33. Outcome 18: WC (cm): sensitivity analysis fixed-effect model",33,NA,0,60,0,61,94.24,6.84,92.35,6.45,0,1.20903606096812,1.89,-0.479667,4.259667,1.46176819672131,90.908203,"33::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Dallio 2021",2021,"Analysis 3.34. Outcome 19: LSM (Kpa)",34,NA,0,30,0,15,4.4,0.7,4.9,1.2,0,0.708754776585903,-0.5,-1.156905,0.156905,0.502333333333333,62.385769,"34::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Dallio 2021",2021,"Analysis 3.34. Outcome 19: LSM (Kpa)",34,NA,0,32,0,15,4.7,1.7,4.9,1.2,0,0.438558243946381,-0.2,-1.045998,0.645998,0.192333333333333,37.614231,"34::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Dallio 2021",2021,"Analysis 3.35. Outcome 20: CAP (dB/m)",35,NA,0,30,0,15,263.9,43.6,272.8,36.8,0,7.99070293111522,-8.9,-33.1947,15.3947,63.8513333333333,49.869238,"35::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Dallio 2021",2021,"Analysis 3.35. Outcome 20: CAP (dB/m)",35,NA,0,32,0,15,305.4,43.4,272.8,36.8,0,12.3720653085893,32.6,8.664039,56.535961,153.068,50.130762,"35::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Cerletti 2020",2020,"Analysis 4.1. Outcome 1: Proportion of participants with serious adverse events",1,NA,0,62,0,64,0,0,0,0,0,0,NA,NA,NA,0,NA,"1::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Fang 2014",2014,"Analysis 4.1. Outcome 1: Proportion of participants with serious adverse events",1,NA,0,150,0,150,0,0,0,0,0,0,NA,NA,NA,0,NA,"1::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Sun 2015a",2015,"Analysis 4.1. Outcome 1: Proportion of participants with serious adverse events",1,NA,0,247,0,247,0,0,0,0,0,0,NA,NA,NA,0,NA,"1::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Cerletti 2020",2020,"Analysis 4.2. Outcome 2: ALT (U/L)",2,NA,0,62,0,64,43.8,22.9,40,21.9,0,0,3.8,-4.02812,11.62812,0,0,"2::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Fang 2014",2014,"Analysis 4.2. Outcome 2: ALT (U/L)",2,NA,0,150,0,150,46.48,7.96,34.18,6.63,0,0,12.3,10.642171,13.957829,0,0,"2::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Cerletti 2020",2020,"Analysis 4.3. Outcome 3: AST (U/L)",3,NA,0,62,0,64,31.6,15,31.2,14.7,0,3.33510697100775,0.4,-4.787591,5.587591,11.1229385080645,0,"3::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Fang 2014",2014,"Analysis 4.3. Outcome 3: AST (U/L)",3,NA,0,150,0,150,31.3,9.44,24.18,9.46,0,0.941879327019479,7.12,4.981302,9.258698,0.887136666666667,0,"3::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Cerletti 2020",2020,"Analysis 4.4. Outcome 4: GGT (U/L)",4,NA,0,62,0,64,87.2,71.1,75.6,64.4,0,0,11.6,-12.109744,35.309744,0,100,"4::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Cerletti 2020",2020,"Analysis 4.5. Outcome 5: Proportion of participants with non-serious adverse events",5,NA,4,62,2,64,0,0,0,0,0,1.01234795262369,2.070306,0.404213,10.603729,0.975754094230284,0,"5::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Fang 2014",2014,"Analysis 4.5. Outcome 5: Proportion of participants with non-serious adverse events",5,NA,0,150,0,150,0,0,0,0,0,0,NA,NA,NA,0,NA,"5::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Sun 2015a",2015,"Analysis 4.5. Outcome 5: Proportion of participants with non-serious adverse events",5,NA,0,247,29,247,0,0,0,0,0,0,0.11998,0.056702,0.253873,0,0,"5::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Cerletti 2020",2020,"Analysis 4.6. Outcome 6: TC (mmol/L)",6,NA,0,62,0,64,5.43,1.47,4.99,1.19,0,0,0.44,-0.027852,0.907852,0,25.979298,"6::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Fang 2014",2014,"Analysis 4.6. Outcome 6: TC (mmol/L)",6,NA,0,150,0,150,5.86,0.93,5.11,0.87,0,0,0.75,0.546201,0.953799,0,74.020702,"6::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Cerletti 2020",2020,"Analysis 4.7. Outcome 6: TC (mmol/L): sensitivity analysis fixed-effect model",7,NA,0,62,0,64,5.43,1.47,4.99,1.19,0,0,0.44,-0.027852,0.907852,0,15.948834,"7::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Fang 2014",2014,"Analysis 4.7. Outcome 6: TC (mmol/L): sensitivity analysis fixed-effect model",7,NA,0,150,0,150,5.86,0.93,5.11,0.87,0,0,0.75,0.546201,0.953799,0,84.051166,"7::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Cerletti 2020",2020,"Analysis 4.8. Outcome 7: TG (mmol/L)",8,NA,0,62,0,64,1.59,0.85,1.43,0.74,0,0,0.16,-0.118629,0.438629,0,36.005536,"8::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Fang 2014",2014,"Analysis 4.8. Outcome 7: TG (mmol/L)",8,NA,0,150,0,150,1.83,0.59,1.44,0.68,0,0,0.39,0.245928,0.534072,0,63.994464,"8::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Cerletti 2020",2020,"Analysis 4.9. Outcome 7: TG (mmol/L): sensitivity analysis fixed-effect model",9,NA,0,62,0,64,1.59,0.85,1.43,0.74,0,0,0.16,-0.118629,0.438629,0,21.096215,"9::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Fang 2014",2014,"Analysis 4.9. Outcome 7: TG (mmol/L): sensitivity analysis fixed-effect model",9,NA,0,150,0,150,1.83,0.59,1.44,0.68,0,0,0.39,0.245928,0.534072,0,78.903785,"9::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Cerletti 2020",2020,"Analysis 4.10. Outcome 8: HDL cholesterol (mmol/L)",10,NA,0,62,0,64,1.3,0.36,1.25,0.33,0,0.146088620640504,0.05,-0.070691,0.170691,0.0213418850806451,0,"10::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Fang 2014",2014,"Analysis 4.10. Outcome 8: HDL cholesterol (mmol/L)",10,NA,0,150,0,150,0.98,0.39,1.2,0.42,0,0.0563914887194867,-0.22,-0.311721,-0.128279,0.00318,0,"10::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Cerletti 2020",2020,"Analysis 4.11. Outcome 9: LDL cholesterol (mmol/L)",11,NA,0,62,0,64,3.36,1.27,3.03,1.11,0,0,0.33,-0.086999,0.746999,0,23.942977,"11::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Fang 2014",2014,"Analysis 4.11. Outcome 9: LDL cholesterol (mmol/L)",11,NA,0,150,0,150,2.47,0.58,1.86,0.57,0,0,0.61,0.479863,0.740137,0,76.057023,"11::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Cerletti 2020",2020,"Analysis 4.12. Outcome 9: LDL cholesterol (mmol/L): sensitivity analysis fixed-effect model",12,NA,0,62,0,64,3.36,1.27,3.03,1.11,0,0,0.33,-0.086999,0.746999,0,8.875066,"12::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Fang 2014",2014,"Analysis 4.12. Outcome 9: LDL cholesterol (mmol/L): sensitivity analysis fixed-effect model",12,NA,0,150,0,150,2.47,0.58,1.86,0.57,0,0,0.61,0.479863,0.740137,0,91.124934,"12::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Cerletti 2020",2020,"Analysis 4.13. Outcome 10: FBS (mmol/L)",13,NA,0,62,0,64,5.75,1.61,5.48,1.64,0,0,0.27,-0.297487,0.837487,0,100,"13::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Cerletti 2020",2020," Analysis 4.14. Outcome 11: HOMA-IR",14,NA,0,62,0,64,4.23,3.46,4.33,2.74,0,0,-0.1,-1.19196,0.99196,0,100,"14::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Cerletti 2020",2020,"Analysis 4.15. Outcome 12: Insulin (pmol/L)",15,NA,0,62,0,64,180,37.9,120,67.4,0,0,60,40.982437,79.017563,0,100,"15::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Cerletti 2020",2020,"Analysis 4.16. Outcome 13: Weight (kg)",16,NA,0,62,0,64,83.9,14.6,88,16.7,0,0,-4.1,-9.57238,1.37238,0,100,"16::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Cerletti 2020",2020,"Analysis 4.17. Outcome 14: BMI (kg/m2)",17,NA,0,62,0,64,30,3.7,31.4,5.3,0,0,-1.4,-2.991936,0.191936,0,100,"17::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Cerletti 2020",2020,"Analysis 4.18. Outcome 15: WC (cm)",18,NA,0,62,0,64,104,12,106,13,0,0,-2,-6.366457,2.366457,0,100,"18::overall","CD015524_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
